Cabozantinib with or without immune checkpoint inhibition in heavily pretreated patients with advanced sarcoma

PURPOSE: The benefit of cabozantinib with or without immune checkpoint inhibition (ICI) in previously heavily treated patients with advanced sarcoma is not clear. EXPERIMENTAL DESIGN: Retrospective study of heavily pretreated advanced sarcoma patients who received cabozantinib with or without ICI. RESULTS: There were 105 eligible patients with thirty-one different histologic subtypes, a median age of 56 years, and 55% were female. The median lines of prior treatment were four. Approximately 40.9% of patients were treated with cabozantinib alone and 59.1% were treated with cabozantinib plus either nivolumab, nivolumab plus ipilimumab, or pembrolizumab. The progression-free survival (PFS) of the full cohort was 3.3 months. Eight patients (7.6%) obtained a partial response (PR), and forty-two patients (40.0%) had stable disease (SD) longer than 3 months, with a clinical benefit rate (CBR) of 47.6%. The median PFS and overall survival (OS) for the 47.6% of patients who obtained a clinical benefit (PR + SD) were 6.9 and 22.9 months, compared to the median PFS of 2.1 months (p < 0.001) and median OS of 7.4 months (p = 0.001) for the patients with progressive disease. Several patients with aggressive histologic subtypes, including osteosarcoma, desmoplastic small round cell tumor, synovial sarcoma, and others, had a PFS of more than 12 months. There was no significant difference in PFS or OS between patients treated with cabozantinib only and patients treated with cabozantinib plus ICI. CONCLUSION: In a cohort of heavily pretreated patients with advanced soft tissue and bone sarcoma, cabozantinib alone or with ICI showed durable CBR in nearly 50% of patients, suggesting cabozantinib alone or with ICI could be a viable treatment option.

Authors

Institutions

Publication Details

Journal
BJC Reports
Published
2026-11-12
DOI
https://doi.org/10.1038/s44276-026-00257-3
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cabozantinib with or without immune checkpoint inhibition in heavily pretreated patients with advanced sarcoma

Nam Q. Bui, Allison K. Pribnow, Joyce Chi, Kristen Nooshin Ganjoo et al.
BJC Reports
Sarcoma Diagnosis and Treatment
article

Cabozantinib with or without immune checkpoint inhibition in heavily pretreated patients with advanced sarcoma

Nam Q. Bui, Allison K. Pribnow, Joyce Chi, Kristen Nooshin Ganjoo, Minggui Pan, Maggie Yuxi Zhou, Andreana Yang Leow, Lauren Jia-Yi Li
article en

Abstract

PURPOSE: The benefit of cabozantinib with or without immune checkpoint inhibition (ICI) in previously heavily treated patients with advanced sarcoma is not clear. EXPERIMENTAL DESIGN: Retrospective study of heavily pretreated advanced sarcoma patients who received cabozantinib with or without ICI. RESULTS: There were 105 eligible patients with thirty-one different histologic subtypes, a median age of 56 years, and 55% were female. The median lines of prior treatment were four. Approximately 40.9% of patients were treated with cabozantinib alone and 59.1% were treated with cabozantinib plus either nivolumab, nivolumab plus ipilimumab, or pembrolizumab. The progression-free survival (PFS) of the full cohort was 3.3 months. Eight patients (7.6%) obtained a partial response (PR), and forty-two patients (40.0%) had stable disease (SD) longer than 3 months, with a clinical benefit rate (CBR) of 47.6%. The median PFS and overall survival (OS) for the 47.6% of patients who obtained a clinical benefit (PR + SD) were 6.9 and 22.9 months, compared to the median PFS of 2.1 months (p < 0.001) and median OS of 7.4 months (p = 0.001) for the patients with progressive disease. Several patients with aggressive histologic subtypes, including osteosarcoma, desmoplastic small round cell tumor, synovial sarcoma, and others, had a PFS of more than 12 months. There was no significant difference in PFS or OS between patients treated with cabozantinib only and patients treated with cabozantinib plus ICI. CONCLUSION: In a cohort of heavily pretreated patients with advanced soft tissue and bone sarcoma, cabozantinib alone or with ICI showed durable CBR in nearly 50% of patients, suggesting cabozantinib alone or with ICI could be a viable treatment option.

BJC ReportsVol. 4(1)
Stanford Medicine (US), Stanford University (US)
Good health and well-being
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon